Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphocytic choriomeningitis virus | 11 | 2018 | 175 | 1.130 |
Why?
|
| Heart-Assist Devices | 7 | 2020 | 1296 | 1.120 |
Why?
|
| Heart Failure | 11 | 2021 | 11840 | 0.630 |
Why?
|
| Arenaviridae Infections | 3 | 2013 | 53 | 0.600 |
Why?
|
| Seawater | 4 | 2021 | 126 | 0.510 |
Why?
|
| Perciformes | 3 | 2021 | 24 | 0.510 |
Why?
|
| Lymphocytic Choriomeningitis | 5 | 2018 | 140 | 0.460 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2018 | 4642 | 0.420 |
Why?
|
| Immunodominant Epitopes | 1 | 2012 | 244 | 0.380 |
Why?
|
| Registries | 6 | 2020 | 8297 | 0.360 |
Why?
|
| Carbon Dioxide | 5 | 2024 | 1137 | 0.340 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 894 | 0.330 |
Why?
|
| Petroleum | 2 | 2019 | 82 | 0.320 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 813 | 0.310 |
Why?
|
| Interferon Type I | 4 | 2018 | 567 | 0.290 |
Why?
|
| Coral Reefs | 3 | 2024 | 36 | 0.280 |
Why?
|
| Potassium | 1 | 2021 | 1311 | 0.280 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 3928 | 0.270 |
Why?
|
| Tricuspid Valve | 1 | 2020 | 422 | 0.270 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 1118 | 0.260 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 538 | 0.260 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 363 | 0.250 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 663 | 0.250 |
Why?
|
| Water Pollutants, Chemical | 2 | 2019 | 358 | 0.250 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 898 | 0.240 |
Why?
|
| Interleukin-2 | 1 | 2012 | 1896 | 0.240 |
Why?
|
| Acclimatization | 1 | 2024 | 113 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8041 | 0.220 |
Why?
|
| Lassa Fever | 2 | 2014 | 97 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 2033 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 2020 | 3310 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 1240 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4348 | 0.180 |
Why?
|
| Fishes | 2 | 2021 | 606 | 0.170 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 1566 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 3446 | 0.150 |
Why?
|
| Virus Replication | 2 | 2018 | 2447 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2024 | 2477 | 0.140 |
Why?
|
| Quality of Life | 4 | 2020 | 13462 | 0.130 |
Why?
|
| Ecosystem | 1 | 2020 | 488 | 0.130 |
Why?
|
| Climate Change | 2 | 2024 | 509 | 0.130 |
Why?
|
| Lassa virus | 2 | 2014 | 100 | 0.130 |
Why?
|
| Murine pneumonia virus | 1 | 2013 | 5 | 0.110 |
Why?
|
| Dystroglycans | 2 | 2011 | 62 | 0.110 |
Why?
|
| Arenavirus | 1 | 2013 | 8 | 0.110 |
Why?
|
| Interferon-beta | 1 | 2015 | 346 | 0.100 |
Why?
|
| Adoptive Transfer | 2 | 2012 | 827 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 12 | 2015 | 22332 | 0.100 |
Why?
|
| Immunological Synapses | 1 | 2012 | 57 | 0.100 |
Why?
|
| Dendritic Cells | 4 | 2013 | 2747 | 0.100 |
Why?
|
| Behavior, Animal | 1 | 2019 | 1865 | 0.100 |
Why?
|
| Virus Internalization | 2 | 2013 | 502 | 0.100 |
Why?
|
| Hypertension | 1 | 2021 | 8626 | 0.090 |
Why?
|
| SSPE Virus | 1 | 2010 | 4 | 0.090 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 2010 | 26 | 0.090 |
Why?
|
| Lung | 1 | 2019 | 10033 | 0.090 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2012 | 169 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1308 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2015 | 910 | 0.090 |
Why?
|
| Viral Fusion Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
| Oceans and Seas | 2 | 2020 | 47 | 0.090 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 989 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2020 | 6853 | 0.090 |
Why?
|
| Animals | 21 | 2024 | 168764 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2020 | 65188 | 0.080 |
Why?
|
| Stroke Volume | 3 | 2021 | 5596 | 0.080 |
Why?
|
| Propylene Glycols | 1 | 2009 | 91 | 0.080 |
Why?
|
| Mice | 14 | 2018 | 81819 | 0.080 |
Why?
|
| Adenosine Deaminase | 1 | 2010 | 251 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 1525 | 0.080 |
Why?
|
| Aged | 9 | 2021 | 171117 | 0.070 |
Why?
|
| Sphingosine | 1 | 2009 | 306 | 0.070 |
Why?
|
| Glycosylation | 1 | 2010 | 1100 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 16721 | 0.070 |
Why?
|
| Male | 14 | 2021 | 363698 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1159 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2020 | 81514 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2010 | 718 | 0.060 |
Why?
|
| Canada | 1 | 2021 | 2119 | 0.060 |
Why?
|
| Point Mutation | 1 | 2011 | 1590 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2015 | 14448 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1624 | 0.060 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 595 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2010 | 1261 | 0.060 |
Why?
|
| Middle Aged | 8 | 2021 | 223009 | 0.060 |
Why?
|
| Female | 13 | 2021 | 396112 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 841 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 1515 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 9550 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2019 | 8067 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2019 | 2652 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 13632 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 12509 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 23601 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2019 | 2105 | 0.050 |
Why?
|
| Humans | 16 | 2021 | 765968 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 1303 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 3690 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 10563 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 18293 | 0.050 |
Why?
|
| Depression | 1 | 2021 | 8237 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 12795 | 0.050 |
Why?
|
| Hospitalization | 3 | 2021 | 10808 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 41649 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4520 | 0.040 |
Why?
|
| United States | 4 | 2021 | 72903 | 0.040 |
Why?
|
| Connecticut | 1 | 2020 | 365 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 2643 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 2966 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2019 | 4184 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2008 | 2921 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2019 | 9347 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 40065 | 0.040 |
Why?
|
| Queensland | 1 | 2017 | 53 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 2904 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 2019 | 248 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8529 | 0.040 |
Why?
|
| Smell | 1 | 2019 | 259 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2009 | 3050 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 4080 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2019 | 907 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 8532 | 0.030 |
Why?
|
| Mice, Inbred NZB | 1 | 2014 | 57 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2018 | 4025 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cell Line | 3 | 2014 | 15543 | 0.030 |
Why?
|
| Pneumovirus Infections | 1 | 2013 | 3 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7425 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 6220 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 18380 | 0.030 |
Why?
|
| H-2 Antigens | 1 | 2013 | 359 | 0.030 |
Why?
|
| Viral Tropism | 1 | 2013 | 101 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2013 | 113 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 953 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2013 | 300 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 21480 | 0.020 |
Why?
|
| Virus Activation | 1 | 2014 | 323 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 59489 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 1175 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 2013 | 3211 | 0.020 |
Why?
|
| Cricetinae | 1 | 2014 | 2411 | 0.020 |
Why?
|
| Fluorescence | 1 | 2013 | 753 | 0.020 |
Why?
|
| Viremia | 1 | 2013 | 727 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2011 | 5881 | 0.020 |
Why?
|
| Forecasting | 1 | 2019 | 2936 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2013 | 825 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 2013 | 640 | 0.020 |
Why?
|
| beta-Alanine | 1 | 2009 | 83 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 341 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2013 | 995 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 147 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2012 | 591 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39193 | 0.020 |
Why?
|
| Cytokines | 2 | 2014 | 7421 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 24282 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 798 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 2669 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2009 | 297 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15747 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 1801 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 2296 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 2825 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 2476 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 30198 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2013 | 1797 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 1718 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 54802 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 223044 | 0.020 |
Why?
|
| Thiophenes | 1 | 2009 | 569 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 2060 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 2599 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 7584 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2010 | 1178 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2013 | 3160 | 0.010 |
Why?
|
| Anxiety | 1 | 2019 | 4671 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 3819 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2013 | 2324 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3807 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4562 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 10261 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2008 | 1250 | 0.010 |
Why?
|
| Actins | 1 | 2010 | 2056 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 74840 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2010 | 1727 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 1874 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2010 | 2920 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 13400 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2817 | 0.010 |
Why?
|
| Stem Cells | 1 | 2014 | 3540 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2010 | 3634 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8703 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 4405 | 0.010 |
Why?
|
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_